首页 › 非小细胞肺癌 › 加利福尼亚州 › San Francisco
San Francisco CA 非小细胞肺癌临床试验
36项针对 非小细胞肺癌的研究正在 San Francisco及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study of ZW251 in Participants With Advanced Solid Tumors
招募中1 期
- UCSF Comprehensive Cancer Center, San Francisco
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
招募中3 期
- UCSF Medical Center at Mission Bay ( Site 0178), San Francisco
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
招募中3 期
- San Francisco Oncology Associates ( Site 0066), San Francisco
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- UCSF Zuckerberg San Francisco General Hospital, San Francisco
Intratumoral N17350 in Advanced Solid Tumors
招募中1/2 期
- University of California, San Francisco, San Francisco
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
招募中3 期
- Research Site, San Francisco
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
招募中3 期
- UCSF Health - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
招募中3 期
- University of California San Francisco, San Francisco
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
招募中1/2 期
- University of California, San Francisco (UCSF), San Francisco
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
招募中2/3 期
- San Francisco Veterans Affairs Medical Center, San Francisco
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
招募中1/2 期
- UCSF Helen Diller Medical Center at Parnassus Heights - Neurology, San Francisco
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
招募中3 期
- California Pacific Medical Center, San Francisco
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
招募中1 期
- University of California San Francisco, San Francisco
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
招募中1 期
- University of California San Francisco, San Francisco
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
招募中1/2 期
- University of California San Francisco, San Francisco
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
招募中3 期
- UCSF Medical Center-Mission Bay, San Francisco
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
招募中2 期
- University of California San Francisco, San Francisco
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
招募中1/2 期
- UCSF Medical Center - Mission Bay, San Francisco
Biomarkers for Risk Stratification in Lung Cancer
招募中观察性研究
- Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco
- San Francisco VA Medical Center, San Francisco
- University of California, San Francisco, San Francisco
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
招募中1 期
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- California Pacific Medical Center-Pacific Campus, San Francisco
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
招募中
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
招募中2 期
- UCSF Medical Center at Mission Bay, San Francisco
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
招募中1/2 期
- University of California at San Francisco, San Francisco
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
招募中1/2 期
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中观察性研究
- Kaiser Permanente-San Francisco, San Francisco
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
招募中1/2 期
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, San Francisco
A Study of NX-1607 in Adults With Advanced Malignancies
招募中1 期
- University of California, San Francisco, San Francisco
A Multicenter Cancer Biospecimen Collection Study
招募中观察性研究
- Curebase, San Francisco
A Study of IBI363 in Subjects with Advanced Solid Malignancies
招募中2 期
- University of California, San Francisco (UCSF), San Francisco
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
San Francisco的其他研究
- 前列腺癌45 项研究
- 乳腺癌43 项研究
- 癌症（所有类型）35 项研究
- 心力衰竭29 项研究
- 转移性癌症28 项研究
- 肺癌22 项研究
- 黑色素瘤22 项研究
- 胰腺癌20 项研究
- 卵巢癌19 项研究
- 结直肠癌18 项研究
- 心血管疾病18 项研究
- 胶质母细胞瘤17 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。